The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis

被引：0
作者：
Richard Conway
Michele F. Doran
Finbar D. O’Shea
Brendan Crowley
Gaye Cunnane
机构：
[1] St. James Hospital,Department of Rheumatology
[2] St. James Hospital,Department of Microbiology
[3] Trinity College,Department of Clinical Medicine
来源：
Clinical Rheumatology | 2014年 / 33卷
关键词：
Disease-modifying antirheumatic drugs; Immunosuppressive Agents; Rheumatoid Arthritis; Screening; Viral hepatitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Identification of patients with exposure to viral hepatitis is an important part of the care of patients with inflammatory arthritis. This study was conducted to assess the extent of hepatitis B and C screening, and the prevalence of viral hepatitis in a cohort of patients with established rheumatoid arthritis (RA). The medical records of 100 consecutive RA patients were retrospectively analysed for screening of hepatitis B surface antigen, surface antibody and core antibody and hepatitis C antibody. A teaching session was then conducted with the rheumatology team, emphasising the rationale for viral hepatitis testing. We then prospectively analysed 100 more RA patients to see if hepatitis screening improved. In the initial 100 patients (21 % male, mean age 65 years), 85 % were taking methotrexate and 22 % biologic treatments. A complete hepatitis screen was present in 8 %, while 12 % had hepatitis B core antibody checked and 53 % had been tested for hepatitis C.
引用
收藏
页码：1823 / 1827
页数：4
相关论文
共 42 条
  • [1] Calabrese LH(2006)Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Ann Rheum Dis 65 983-989
  • [2] Zein NN(2008)Recommendations for identification and public health management of persons with chronic hepatitis B virus infection MMWR Recomm Rep 57 1-20
  • [3] Vassilopoulos D(2011)Let the fog be lifted: screening for hepatitis B virus before biological therapy Ann Rheum Dis 70 1701-1703
  • [4] Weinbaum CM(2012)2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res (Hoboken) 64 625-639
  • [5] Williams I(1988)The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315-324
  • [6] Mast EE(2007)Occult hepatitis B infection J Hepatol 46 160-170
  • [7] Winthrop KL(2011)Kinetics of viral loads and risk of HBV reactivation in HBcAb positive RA patients undergoing anti-TNF-α therapy Ann Rheum Dis 70 1719-1725
  • [8] Calabrese LH(2011)Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients Mod Rheumatol 21 16-23
  • [9] Singh JA(2009)A comparison of hepatitis B seroepidemiology in ten European countries Epidemiol Infect 137 961-969
  • [10] Furst DE(2012)Determination of the burden of hepatitis C virus infection in Ireland Epidemiol Infect 140 1461-1468
12345